TNXP trades 397.2% below Wall Street's consensus target of $27.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TNXP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 22, 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) has a Wall Street consensus price target of $27.00, based on estimates from 7 covering analysts. With the stock currently trading at $5.43, this represents a potential upside of +397.2%. The company has a market capitalization of $87M.
Analyst price targets range from a low of $27.00 to a high of $27.00, representing a 0% spread in expectations. The median target of $27.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TNXP trades at a trailing P/E of -0.4x. Analysts expect EPS to grow -2.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AXSMAxsome Therapeutics, Inc. | $8.0B | $156.31 | $283.00 | +81.1% | Buy | — | 27 |
 INVAInnoviva, Inc. | $1.5B | $20.91 | $38.00 | +81.7% | Buy | 8.6x | 10 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.4B | $41.21 | $57.60 | +39.7% | Buy | 16.3x | 14 |
 CORTCorcept Therapeutics Incorporated | $12.5B | $116.28 | $125.33 | +7.8% | Buy | 57.1x | 26 |
 PCRXPacira BioSciences, Inc. | $1.4B | $36.33 | $31.67 | -12.8% | Hold | 12.5x | 36 |
 JAZZJazz Pharmaceuticals plc | $13.3B | $211.97 | $292.80 | +38.1% | Buy | 8.6x | 48 |
 AVPTAvePoint, Inc. | $3.3B | $15.72 | $15.20 | -3.3% | Buy | 35.6x | 13 |
 PTCTPTC Therapeutics, Inc. | $5.2B | $62.62 | $102.50 | +63.7% | Buy | 49.9x | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.5B | $20.19 | $29.95 | +48.3% | Buy | 32.4x | 37 |
 NKTRNektar Therapeutics | $1.3B | $38.27 | $130.43 | +241.0% | Buy | — | 33 |
Quick answers to the most common questions about buying TNXP stock.
The consensus Wall Street price target for TNXP is $27, representing 397.2% upside from the current price of $5.43. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TNXP has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $27 implies 397.2% upside from current levels.
TNXP's current price is $5.43 with a consensus target of $27 (397.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $27 for TNXP, while the most conservative target is $27. The consensus of $27 represents the median expectation. These targets typically reflect 12-month expectations.
TNXP is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TNXP stock forecast based on 7 Wall Street analysts shows a consensus price target of $27, with estimates ranging from $27 (bear case) to $27 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TNXP, with a "Buy" consensus rating and $27 price target (397.2% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TNXP analyst price targets range from $27 to $27, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $27 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.